Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Cencic, Regina ^a   Carrier, Marilyn ^a   Galicia Vázquez, Gabriela ^a   Bordeleau, Marie Eve ^a   Sukarieh, Rami ^a   Bourdeau, Annie ^b   Brem, Brigitte ^d   Teodoro, Jose G ^a,c   Greger, Harald ^d   Tremblay, Michel L ^a,c   Porco Jr , John A ^e   Pelletier, Jerry ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF VIENNA   (Austria)

^e Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOFURAN DERIVATIVE; DOXORUBICIN; INITIATION FACTOR 4A; MESSENGER RNA; RAPAMYCIN; SILVESTROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INITIATION FACTOR 4E; RNA; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; RIBOSOME; STRUCTURE ACTIVITY RELATION; TRANSLATION INITIATION; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; PROTEIN SYNTHESIS; TUMOR CELL LINE; XENOGRAFT;

AGLAIA; ANIMALIA; EUKARYOTA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA, NEOPLASM; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES;

EID: 65549098672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005223     Document Type: Article

References (53)

1. Ohse T, Ohba S, Yamamoto T, Koyano T, Umezawa K (1996) Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. J Nat Prod 59: 650-652.
2. Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM (1998) Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chemico-Biol Interact 115: 215-228.
3. Gerard B, Cencic R, Pelletier J, Porco JAJ (2007) Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew Chem Int Ed Engl 46: 7831-7834.
4. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM-H, et al. (2008) Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Inv 118: 1-11.
5. Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, et al. (2004) Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem 69: 3350-3358.
6. Meurer-Grimes BM, Yu J, Vairo GL (2004) Therapeutic compounds and methods. USA: The Government of the State of Sarawak, Malaysia. 28 p.
7. Mi Q, Su BN, Chai H, Cordell GA, Farnsworth NR, et al. (2006) Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells. Anticancer Res 26: 947-952.
8. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, et al. (2001) Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci U S A 98: 7029-7036.
9. Grifo JA, Tahara SM, Leis JP, Morgan MA, Shatkin AJ, et al. (1982) Characterization of eukaryotic initiation factor 4A, a protein involved in ATP-dependent binding of globin mRNA. J Biol Chem 257: 5246-5252.
10. Edery I, Humbelin M, Darveau A, Lee KA, Milburn S, et al. (1983) Involvement of eukaryotic initiation factor 4A in the cap recognition process. J Biol Chem 258: 11398-11403.
11. Rogers GW, Jr, Komar AA, Merrick WC (2002) eIF4A: The godfather of the DEAD box helicases. Prog Nucleic Acid Res Mol Biol 72: 307-331.
12. Raught B, Gingras A-C, Sonenberg N (2000) Regulation of Ribosome Recruitment in Eukaryotes Sonenberg N, Hershey JWB, Mathews MB, eds. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. pp 245-293.
13. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, et al. (2006) S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471.
14. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199.
15. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 59 cap. Nature 345: 544-547.
16. Wendel H-G, de Stanchina E, Fridman JS, Malina A, Ray S, et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
17. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68: 631-634.
18. Jiang L, Suri AK, Fiala R, Patel DJ (1997) Saccharide-RNA recognition in an aminoglycoside antibiotic-RNA aptamer complex. Chem Biol 4: 35-50.
19. Greenberg JR (1981) The polyribosomal mRNA-protein complex is a dynamic structure. Proc Natl Acad Sci U S A 78: 2923-2926.
20. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, et al. (2006) RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol 13: 1287-1295.
21. Lindqvist L, Oberer M, Reibarkh M, Cencic R, Bordeleau M-E, et al. (2008) Selective Pharmacological Targetting of a DEAD box RNA Helicase. PLoS ONE 3: e1583.
22. Sonenberg N (1981) ATP/Mg++-dependent cross-linking of cap binding proteins to the 59 end of eukaryotic mRNA. Nucleic Acids Res 9: 1643-1656.
23. Kumari S, Bugaut A, Huppert J, Balasubramanian S (2007) An RNA Gquadruplex in the 59 UTR of the NRAS proto-oncogene modulates translation. Nat Chem Biol 3: 218-221.
24. Pestova TV, Kolupaeva VG (2002) The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev 16: 2906-2922.
25. Pestova TV, Shatsky IN, Fletcher SP, Jackson RJ, Hellen CU (1998) A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev 12: 67-83.
26. Bordeleau M-E, Mori A, Oberer M, Lindqvist L, Chard LS, et al. (2006) Functional Characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2: 213-220.
27. Parkin NT, Cohen EA, Darveau A, Rosen C, Haseltine W, et al. (1988) Mutational analysis of the 59 non-coding region of human immunodeficiency virus type 1: effects of secondary structure on translation. EMBO J 7: 2831-2837.
28. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, et al. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5: 553-563.
29. Majumder PK, Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
30. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, et al. (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505.
31. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, et al. (2003) Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901.
32. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, et al. (2007) Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2: e242.
33. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, et al. (2006) Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66: 7639-7646.
34. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
35. Graff JR, Zimmer SG (2003) Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Met 20: 265-273.
36. Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, et al. (2008) Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 22: 2178-2188.
37. Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, et al. (1996) Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16: 6573-6581.
38. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, et al. (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295: 140-143.
39. Morley SJ, McKendrick L (1997) Involvement of stress-activated protein kinase and p38/RK mitogen-activated protein kinase signaling pathways in the enhanced phosphorylation of initiation factor 4E in NIH 3T3 cells. J Biol Chem 272: 17887-17893.
40. Tee AR, Proud CG (2000) DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 19: 3021-3031.
41. Mungamuri SK, Yang X, Thor AD, Somasundaram K (2006) Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66: 4715-4724.
42. Kim S, Salim AA, Swanson SM, Kinghorn AD (2006) Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem 6: 319-345.
43. Anthony TG, Anthony JC, Yoshizawa F, Kimball SR, Jefferson LS (2001) Oral administration of leucine stimulates ribosomal protein mRNA translation but not global rates of protein synthesis in the liver of rats. J Nutr 131: 1171-1176.
44. Lin C-J, Cencic R, Mills JR, Robert F, Pelletier J (2008) c-Myc and eIF4F are Components of a Feedforward Loop that Link Transcription and Translation. Cancer Res 68: 5326-5334.
45. Mills JR, Hippo Y, Robert F, Chen SMH, Malina A, et al. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 105: 10853-10858.
46. Novac O, Guenier AS, Pelletier J (2004) Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 32: 902-915.
47. Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, et al. (2001) The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 59 secondary structure. RNA 7: 382-394.
48. Merrick WC, Sonenberg N (1997) Assays for eukaryotic translation factors that bind mRNA. Methods 11: 333-342.
49. Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, et al. (2002) Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. Hum Mol Genet 11: 3007-3017.
50. Mazroui R, Sukarieh R, Bordeleau ME, Kaufman RJ, Northcote P, et al. (2006) Inhibition of ribosome recruitment induces stress granule formation independently of eukaryotic initiation factor 2alpha phosphorylation. Mol Biol Cell 17: 4212-4219.
51. Kimball SR, Horetsky RL, Ron D, Jefferson LS, Harding HP (2003) Mammalian stress granules represent sites of accumulation of stalled translation initiation complexes. Am J Physiol Cell Physiol 284: C273-284.
52. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Canc Inst 82: 1107-1112.
53. Chou T, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple durgs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.